Key facts
- Chinese innovative drugs, including ADCs, showed strong data at ESMO 2026.
- 29 Chinese innovative drug studies were selected for LBAs, with 5 in the Presidential Symposium.
- Akesobio's Ivonesi showed positive Phase III results in advanced biliary tract cancer.
- Bio-Thera Solutions' seltugralist demonstrated potential in extensive-stage small cell lung cancer.
- Innovent Biologics presented updated data on its ovarian cancer and solid tumor pipeline.
- Simcere Pharmaceutical reported favorable safety and preliminary efficacy for CMDE005.
Chinese pharmaceutical companies are increasingly making their mark on the global oncology stage, as evidenced by their significant presence and positive data presentations at the European Society for Medical Oncology (ESMO) Congress 2026. The event, held in Madrid from October 23-27, saw a substantial number of Chinese innovative drug research submissions, with 29 late-breaking abstracts (LBAs) and five studies selected for the prestigious Presidential Symposium. This marks a significant leap in both quantity and quality compared to previous years, underscoring China's growing capabilities in drug discovery and development. Companies like Akesobio, Bio-Thera Solutions, Innovent Biologics, and Simcere Pharmaceutical presented data on novel cancer therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, many of which are advancing to or have completed Phase III clinical trials. This shift towards global Phase III validation signifies a maturation of the Chinese biotech sector, moving from early-stage efficacy demonstrations to providing robust, evidence-based data for regulatory approval and commercialization worldwide.